Mdoloris
Financials
Estimates*
EUR | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Revenues | 1.8m | 2.2m | 2.3m | 2.7m | 2.7m | 2.7m |
% growth | - | 19 % | 6 % | 15 % | - | - |
EBITDA | - | (2.0m) | (1.6m) | - | - | - |
% EBITDA margin | - | (92 %) | (67 %) | - | - | - |
Profit | (1.3m) | (2.3m) | (2.0m) | - | - | - |
% profit margin | (68 %) | (105 %) | (85 %) | - | - | - |
Source: Dealroom estimates
Recent News about Mdoloris
EditMDoloris Medical Systems specializes in developing advanced pain monitoring devices and technologies aimed at enhancing patient care and safety. The company operates in the medical technology market, focusing on both conscious and unconscious patients across various clinical settings, including operating rooms (OR) and intensive care units (ICU). MDoloris' core product, the ANI (Analgesia Nociception Index) technology, measures the Autonomic Nervous System to help clinicians monitor the balance between analgesia and nociception, thereby improving pain management. The company collaborates with global medical technology leaders like Masimo to integrate its ANI technology into broader monitoring platforms, such as the ANI MOC 9 module within the ROOT monitor platform. This integration allows for more precise treatment options, ensuring better patient outcomes. MDoloris generates revenue through the sale of its monitoring devices and technology modules, targeting hospitals, clinics, and healthcare providers worldwide. The company's business model is centered around continuous innovation and collaboration to provide state-of-the-art solutions for pain management.
Keywords: pain monitoring, ANI technology, analgesia management, surgical stress, ICU, OR, patient care, medical devices, Masimo collaboration, healthcare technology.